MediciNova Inc
Suletud
SektorTervishoid
1.78 4.71
Ülevaade
Aktsiahinna muutus
24h
Min
1.7
Max
1.76
Sissetulek | -2.3B -2.3B |
|---|---|
Müük | 271K 458K |
Aktsiakasum | -0.05 |
Kasumimarginaal | -504,786.678 |
Töötajad | 6 |
EBITDA | 5.1K -2.5M |
Järgmine tulemuste avaldamine | 10. nov 2026 |
|---|
Turukapital | 15M 80M |
|---|---|
Eelmine avamishind | -2.93 |
Eelmine sulgemishind | 1.78 |
Uudiste sentiment
By Acuity
34%
66%
86 / 339 Pingereas Healthcare
MediciNova Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
MediciNova Inc Prognoos
Sentiment
By Acuity
86 / 339 Pingereas Tervishoid
Uudiste sentiment
Languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.